Multiplex Assay Kit for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay)

FH3; HCHOLA3; NARC1; Hypercholesterolemia,Autosomal Dominant 3; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 92-99 95
EDTA plasma(n=5) 78-94 86
heparin plasma(n=5) 88-96 93

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 92-101% 99-105% 78-101% 78-89%
EDTA plasma(n=5) 80-92% 78-92% 85-103% 85-93%
heparin plasma(n=5) 97-105% 81-92% 93-101% 81-97%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PCSK9) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Biological Trace Element Research Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers pubmed:28409410
BASIC RESEARCH IN CARDIOLOGY Autocrine effects of PCSK9 on cardiomyocytes Pubmed: 33169229
J Transl Med Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555
Metabolism MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice 33775647
Eur Rev Med Pharmacol Sci Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders 34533801
Clin Exp Hypertens Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease Pubmed:35502687
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPE189Ra01 Recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Positive Control; Immunogen; SDS-PAGE; WB.
PAE189Ra01 Polyclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) WB; IHC; ICC; IP.
MAE189Ra23 Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) WB; IHC; ICC; IP.
MAE189Ra22 Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) WB; IHC; ICC; IP.
MAE189Ra21 Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) WB; IHC
SEE189Ra ELISA Kit for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Enzyme-linked immunosorbent assay for Antigen Detection.
LME189Ra Multiplex Assay Kit for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.